HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on ADMA Biologics and raised the price target from $10 to $18.
August 12, 2024 | 10:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on ADMA Biologics and raised the price target from $10 to $18.
The raised price target from $10 to $18 by HC Wainwright & Co. indicates strong confidence in ADMA Biologics' future performance. This is likely to positively impact the stock price in the short term as investors react to the bullish outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100